<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03660748</url>
  </required_header>
  <id_info>
    <org_study_id>MET-3 101</org_study_id>
    <nct_id>NCT03660748</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of MET-3 in Obese Human Subjects</brief_title>
  <official_title>A Phase I, Open-Label, Single-Centre Study of the Safety and Efficacy of Microbial Ecosystem Therapeutics (MET)-3 in Obese Human Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NuBiyota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Glycemic Index Laboratories, Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>NuBiyota</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A pilot study to explore the metabolic effect and safety of a 3-week course of therapy with&#xD;
      MET-3 in obese subjects&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label, single center, uncontrolled pilot study of 20 participants; each group&#xD;
      will receive a different dose of MET-3. Each group will have 4-6 females, 4-6 participants&#xD;
      with BMI 30.0-34.9 kg/m² and the remainder with BMI 35-39.9 kg/m.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Actual">January 22, 2020</completion_date>
  <primary_completion_date type="Actual">January 22, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study design is open label, single center, uncontrolled pilot study of 20 participants divided into 2 groups of 10; each group will receive a different dose of MET-3. Each group will have 4-6 females, 4-6 participants with BMI 30.0-34.9 kg/m² and the remainder with BMI 35-39.9 kg/m.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of MET-3 on the Incremental Area under the glucose curve (2 hrs) in obese subjects</measure>
    <time_frame>Treatment week 6</time_frame>
    <description>The area under the glucose curve in obese subjects will be measured 2 hours after a 75 g oral glucose challenge. This measurement will be made at baseline and then again after 6 weeks of treatment with MET-3.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>Period beginning at enrollment and continuing through to end of treatment phase (week 6)</time_frame>
    <description>Adverse Events,Complete blood count (CBC), aspartate transaminase (AST), alanine aminotransferase (ALT), Alkaline phosphatase (ALP), bilirubin, urea, amylase, creatinine and electrolytes</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Lower BMI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use of MET-2 in subjects with BMI of 30.0 to 34.9</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Higher BMI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use of MET-2 in subjects with BMI of 35 to 39.9</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MET-2</intervention_name>
    <description>Ingestion of a novel human microbiome preparation</description>
    <arm_group_label>Higher BMI</arm_group_label>
    <arm_group_label>Lower BMI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or non-pregnant, non-lactating females who are taking adequate contraceptive&#xD;
             precaution, aged 18 to 75 years inclusive;&#xD;
&#xD;
          2. BMI ≥30.0 kg/m2 and &lt;40.0 kg/m2;&#xD;
&#xD;
          3. Stable body weight (±4 kg) for the past 4 months with no intention to gain or lose&#xD;
             weight;&#xD;
&#xD;
          4. Fasting serum triglycerides &lt;6 mmol/L (&lt;532 mg/dL) at screening;&#xD;
&#xD;
          5. Fasting serum glucose &lt;7.0 mmol/L (&lt;126 mg/dl) and A1c&lt;6.5% at screening&#xD;
&#xD;
          6. Blood pressure &lt;160/100.&#xD;
&#xD;
          7. AST, ALT and ALP ≤1.8 times the upper limit of normal (liver function) at screening;&#xD;
&#xD;
          8. Serum creatinine &lt; 1.5 times the upper limit of normal (kidney function) at screening;&#xD;
&#xD;
          9. At least one of the following:&#xD;
&#xD;
               -  Fasting serum glucose &gt;5.6 mmol/L&#xD;
&#xD;
               -  HbA1c &gt; 6.0%&#xD;
&#xD;
               -  Fasting triglycerides &gt;1.70 mmol/L (150 mg/dl)&#xD;
&#xD;
               -  AST &gt; upper limit of normal&#xD;
&#xD;
               -  Blood pressure, systolic &gt;140 mmHg and/or diastolic &gt;90 mmHg&#xD;
&#xD;
         10. Willing to maintain habitual diet, physical activity pattern, and body weight&#xD;
             throughout the trial;&#xD;
&#xD;
         11. Willing to abstain from strenuous exercise, consuming alcoholic drinks 24 hours before&#xD;
             study days and during study days;&#xD;
&#xD;
         12. Willing to maintain current dietary supplement and medication use throughout the&#xD;
             trial. On test days, subject agrees to bring any dietary supplements or medications&#xD;
             taken in the morning with them to GI labs to take just prior to the glucose test meal;&#xD;
&#xD;
         13. Subject is not currently participating nor recently (within 30 days of screening)&#xD;
             participated in a clinical trial involving long-term exposure (greater than 24 hours)&#xD;
             to an investigational drug, nutritional supplement or lifestyle modification;&#xD;
&#xD;
         14. Understanding the study procedures and willing to provide informed consent to&#xD;
             participate in the study and authorization to release relevant protected health&#xD;
             information to the study investigator and other authorized agents as indicated in the&#xD;
             consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Failure to meet any one of the inclusion criteria.&#xD;
&#xD;
          2. Smokers&#xD;
&#xD;
          3. Hemoglobin measurements of &lt;120g/L for females and &lt;130g/L for males (as per World&#xD;
             Health Organization [WHO] criteria for anemia)&#xD;
&#xD;
          4. Known history of acquired immune deficiency syndrome (AIDS), hepatitis, a history or&#xD;
             presence of clinically important endocrine conditions (including Type 1 or Type 2&#xD;
             diabetes mellitus), pulmonary, biliary or gastrointestinal (GI) disorders or new onset&#xD;
             cardiovascular disease within 6 months of screening (including, but not limited to,&#xD;
             atherosclerotic disease, history of myocardial infarction, peripheral arterial&#xD;
             disease, stroke).&#xD;
&#xD;
          5. Use of medications known to influence carbohydrate metabolism, gastrointestinal&#xD;
             function or appetite, including, but not limited to adrenergic blockers, diuretics,&#xD;
             thiazolidinediones, metformin and systemic corticosteroids within 4 weeks of the&#xD;
             screening visit, or with any condition which might, in the opinion of the&#xD;
             Investigator, either: 1) make participation dangerous to the subject or to others, 2)&#xD;
             affect the results, or 3) influence the ability of the subject to comply with study&#xD;
             procedures.&#xD;
&#xD;
          6. Major trauma or surgical event within 3 months of screening.&#xD;
&#xD;
          7. Unwillingness or inability to comply with the experimental procedures and to follow GI&#xD;
             Labs safety guidelines.&#xD;
&#xD;
          8. Known intolerance, sensitivity or allergy to any ingredients in the investigational&#xD;
             agent.&#xD;
&#xD;
          9. Extreme dietary habits, as judged by the Investigator (i.e. Atkins diet, very high&#xD;
             protein diets, etc.).&#xD;
&#xD;
         10. Uncontrolled hypertension (systolic blood pressure ≥160 mm Hg or diastolic blood&#xD;
             pressure ≥100 mm Hg as defined by the average blood pressure measured at screening.&#xD;
&#xD;
         11. Presence of any signs or symptoms of an active infection within 5 d prior to any test&#xD;
             visit. If an infection occurs during the study period, test visits should be&#xD;
             rescheduled until all signs and symptoms have resolved and any treatment (i.e.&#xD;
             antibiotic therapy) has been completed at least 5 d prior to each test visit.&#xD;
&#xD;
         12. History of cancer in the prior two years, except for non-melanoma skin cancer.&#xD;
&#xD;
         13. Recent history (within 12 months of screening) or strong potential for alcohol or&#xD;
             substance abuse. Alcohol abuse is defined as &gt; 14 drinks per week (1 drink=12 oz beer,&#xD;
             5 oz wine, or 1.5 oz distilled spirits).&#xD;
&#xD;
         14. Pregnancy or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>4 - 6 non-pregnant, non-lactating females in each group of 10 subjects</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas MS Wolever, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>GI Labs</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GI Labs</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5C2N8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>August 28, 2018</study_first_submitted>
  <study_first_submitted_qc>September 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2018</study_first_posted>
  <last_update_submitted>August 10, 2020</last_update_submitted>
  <last_update_submitted_qc>August 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>human microbiota</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

